Jump to content

Recommended Posts

Posted

The status of the HPAI H7N9 case(s)/cluster in Qingyuan remains confused.  CHP initially reported a case (57M) in Qingyaun, Guangdong province as "under investigation.  

On Feb 19 the Guangdong (GD) CDC released a full H7N9 sequence from Qingyuan that was HPAI (poly-basic cleavage site) with Tamiflu resistance (R292K) and PB2 mammalian adaptation (E627K).  The collection date was Jan 14 from a fatal case (56M) which was similar to the above CHP case.

On Feb 20 WHO (Beijing) release a full sequence which was vitually identical to the above sequence.Segments were identical (H7,MP,NP,NS), had a single difference (N9,PB2,PA) or 2 differences (PB1) suggesting the sequence was from the same case (which Beijing said was also 56M collected a week earlier (Jan 7).

However,the next day WHO modified teh collection date (to Jan 12) and changed age from 56 to 57 (which matched the CHP data).

Today WHO issued an update on HPAI cases and cited a 57M case who was symptomatic on Jan 5 and was in critical condition (as of Feb 22).

Thus, it is unclear if the two closely related sequences are from one case with an age and status discrepancy (56 or 57) and (dead in January or critical in February) or are from two individuals at the same location (Qinyuan) collected within days of each other,and virtually identical,signaling a cluster.

Posted
Isolate name:
 
A/Qingyuan/GIRD1/2017 
 
 
Isolate ID:
 
EPI_ISL_249102 
 
 
Passage details/history:
 
 
 
 
Type:
 
A / H7N9 
 
 
Lineage:
 
 
Sample information

 

Collection date:
 
2017-01-14 
 
 
Host
 
Human 
 
 
Additional host information:
 
 
 
 
Zip code:
 
 
 
 
Patient status:
 
Deceased 
 
 
Last vaccinated:
 
 
 
 
In-vivo pathogenicity test:
 
 
 
 
Location:
 
China / Guangdong Province 
 
 
Additional location information:
 
 
 
 
Patient age:
 
56 Year(s) 
 
 
Gender:
 
Male 
 
 
Outbreak:
 
Sporadic 
 
 
Treatment:
 
Treatment by Oseltamivir  
 
 
Specimen source:
 
Tracheal 
 
 
Institute information

 

Originating lab:
 
State Key Laboratory of Reipiratory Disease (Guangzhou Medical University)
 
Sample ID given by the sample provider:
 
 
 
 
Address:
 
State Key Laboratory of Reipiratory Disease (Guangzhou Medical University)
 195, Dongfengxi Road, Yuexiu District, Guangzhou, Guangdong Province, China,  
Guangzhou 
China
 
Submitting lab:
 
guangzhou institute of respiratory disease
 
Sample ID given by the submitting laboratory:
 
 
 
 
Authors:
 
Wenda Guan,PhD;
Wenjun Song,PhD;
Jianfeng He,MD;
Changwen Ke,MD;
Zifeng Yang,PhD;
Haibo Zhou,MD;
Qinhan Lin,MD;
Yonghui Zhang,MD;
Nanshan Zhong,MD
 
Address:
 
guangzhou institute of respiratory disease
 1 kangda road,  
guangzhou 
China
 
Publication
Publication
 
In vivo antiviral resistance

 

Antiviral resistance tested by experimental procedures
 
Adamantanes:
 
Unknown 
 
 
Oseltamivir:
 
Unknown 
 
 
Zanamivir:
 
Unknown 
 
 
Peramivir:
 
Unknown 
 
 
Other:
 
Unknown 
 
 
Additional information
Antigenic characterization:
 
 
 
 
Note:
 
 
 
 
Sequence

 

segment identifier length accession # INSDC Sequence
 
PB2
 
A/Qingyuan/GIRD1/2017
 
2341
 
EPI918730
 
 
 
 
PB1
 
A/Qingyuan/GIRD1/2017
 
2341
 
EPI918732
 
 
 
 
PA
 
A/Qingyuan/GIRD1/2017
 
2233
 
EPI918734
 
 
 
 
HA
 
A/Qingyuan/GIRD1/2017
 
1744
 
EPI918736
 
 
 
 
NP
 
A/Qingyuan/GIRD1/2017
 
1565
 
EPI918737
 
 
 
 
NA
 
A/Qingyuan/GIRD1/2017
 
1444
 
EPI918738
 
 
 
 
MP
 
A/Qingyuan/GIRD1/2017
 
1027
 
EPI918739
 
 
 
 
NS
 
A/Qingyuan/GIRD1/2017
 
890
 
EPI918740
 
 
 
Submitter information

 

Submitter:
 
guan, wenda  
 
 
Submission Date:
 
2017-02-19 
 
 
Last modifier:
 
guan, wenda  
 
 
Last modified:
 
2017-02-19 
 
 
Address:
 
guangzhou institute of respiratory disease
 1 kangda road,  
guangzhou 
China
Posted
Isolate name:
 
A/Guangdong/17SF006/2017 
 
 
Isolate ID:
 
EPI_ISL_249308 
 
 
Passage details/history:
 
E1 
 
 
Type:
 
A / H7N9 
 
 
Lineage:
 
 
Sample information

 

Collection date:
 
2017-01-07 
 
 
Host
 
Human 
 
 
Additional host information:
 
 
 
 
Zip code:
 
 
 
 
Patient status:
 
 
 
 
Last vaccinated:
 
 
 
 
In-vivo pathogenicity test:
 
 
 
 
Location:
 
China 
 
 
Additional location information:
 
Guangdong 
 
 
Patient age:
 
56 Year(s) 
 
 
Gender:
 
Male 
 
 
Outbreak:
 
 
 
 
Treatment:
 
 
 
 
Specimen source:
 
 
 
 
Institute information

 

Originating lab:
 
 
 
Sample ID given by the sample provider:
 
 
 
 
Address:
 
 
 
Submitting lab:
 
WHO Chinese National Influenza Center
 
Sample ID given by the submitting laboratory:
 
 
 
 
Authors:
 
 
 
Address:
 
WHO Chinese National Influenza Center
Virology Institute, Chinese CDC
 155 Changbai Road, Changping District,  
Beijing 102206
China
 
Publication
Publication
 
In vivo antiviral resistance

 

Antiviral resistance tested by experimental procedures
 
Adamantanes:
 
Unknown 
 
 
Oseltamivir:
 
Unknown 
 
 
Zanamivir:
 
Unknown 
 
 
Peramivir:
 
Unknown 
 
 
Other:
 
Unknown 
 
 
Additional information
Antigenic characterization:
 
 
 
 
Note:
 
 
 
 
Sequence

 

segment identifier length accession # INSDC Sequence
 
PB2
 
A/Guangdong/17SF006/2017-PB2
 
2280
 
EPI919596
 
 
 
 
PB1
 
A/Guangdong/17SF006/2017-PB1
 
2274
 
EPI919597
 
 
 
 
PA
 
A/Guangdong/17SF006/2017-PA
 
2151
 
EPI919595
 
 
 
 
HA
 
A/Guangdong/17SF006/2017-HA
 
1695
 
EPI919599
 
 
 
 
NP
 
A/Guangdong/17SF006/2017-NP
 
1497
 
EPI919592
 
 
 
 
NA
 
A/Guangdong/17SF006/2017-NA
 
1398
 
EPI919598
 
 
 
 
MP
 
A/Guangdong/17SF006/2017-MP
 
982
 
EPI919594
 
 
 
 
NS
 
A/Guangdong/17SF006/2017-NS
 
838
 
EPI919593
 
 
 
Submitter information

 

Submitter:
 
Yang, Lei  
 
 
Submission Date:
 
2017-02-20 
 
 
Last modifier:
 
Yang, Lei  
 
 
Last modified:
 
2017-02-20 
 
 
Address:
 
WHO Chinese National Influenza Center
Virology Institute, Chinese CDC
 155 Changbai Road, Changping District,  
Beijing 102206
China
Posted
Isolate name:
 
A/Guangdong/17SF006/2017 
 
 
Isolate ID:
 
EPI_ISL_249308 
 
 
Passage details/history:
 
E1 
 
 
Type:
 
A / H7N9 
 
 
Lineage:
 
 
Sample information

 

Collection date:
 
2017-01-12 
 
 
Host
 
Human 
 
 
Additional host information:
 
 
 
 
Zip code:
 
 
 
 
Patient status:
 
 
 
 
Last vaccinated:
 
 
 
 
In-vivo pathogenicity test:
 
 
 
 
Location:
 
China 
 
 
Additional location information:
 
Guangdong 
 
 
Patient age:
 
57 Year(s) 
 
 
Gender:
 
Male 
 
 
Outbreak:
 
 
 
 
Treatment:
 
 
 
 
Specimen source:
 
 
 
 
Institute information

 

Originating lab:
 
 
 
Sample ID given by the sample provider:
 
 
 
 
Address:
 
 
 
Submitting lab:
 
WHO Chinese National Influenza Center
 
Sample ID given by the submitting laboratory:
 
 
 
 
Authors:
 
 
 
Address:
 
WHO Chinese National Influenza Center
Virology Institute, Chinese CDC
 155 Changbai Road, Changping District,  
Beijing 102206
China
 
Publication
Publication
 
In vivo antiviral resistance

 

Antiviral resistance tested by experimental procedures
 
Adamantanes:
 
Unknown 
 
 
Oseltamivir:
 
Unknown 
 
 
Zanamivir:
 
Unknown 
 
 
Peramivir:
 
Unknown 
 
 
Other:
 
Unknown 
 
 
Additional information
Antigenic characterization:
 
 
 
 
Note:
 
 
 
 
Sequence

 

segment identifier length accession # INSDC Sequence
 
PB2
 
A/Guangdong/17SF006/2017-PB2
 
2280
 
EPI919596
 
 
 
 
PB1
 
A/Guangdong/17SF006/2017-PB1
 
2274
 
EPI919597
 
 
 
 
PA
 
A/Guangdong/17SF006/2017-PA
 
2151
 
EPI919595
 
 
 
 
HA
 
A/Guangdong/17SF006/2017-HA
 
1695
 
EPI919599
 
 
 
 
NP
 
A/Guangdong/17SF006/2017-NP
 
1497
 
EPI919592
 
 
 
 
NA
 
A/Guangdong/17SF006/2017-NA
 
1398
 
EPI919598
 
 
 
 
MP
 
A/Guangdong/17SF006/2017-MP
 
982
 
EPI919594
 
 
 
 
NS
 
A/Guangdong/17SF006/2017-NS
 
838
 
EPI919593
 
 
 
Submitter information

 

Submitter:
 
Yang, Lei  
 
 
Submission Date:
 
2017-02-20 
 
 
Last modifier:
 
Yang, Lei  
 
 
Last modified:
 
2017-02-21 
 
 
Address:
 
WHO Chinese National Influenza Center
Virology Institute, Chinese CDC
 155 Changbai Road, Changping District,  
Beijing 102206
China

Please sign in to comment

You will be able to leave a comment after signing in



Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.
×
×
  • Create New...